Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Marker Therapeutics ( (MRKR) ) just unveiled an announcement.
On August 26, 2025, Marker Therapeutics announced encouraging results from its Phase 1 APOLLO study, which investigates the MT-601 product in patients with relapsed B cell lymphoma. The study showed a 66% objective response rate in Non-Hodgkin Lymphoma patients, with 50% achieving complete response, and a favorable safety profile with no dose-limiting toxicities. The dose expansion phase will focus on patients with Diffuse Large B Cell Lymphoma who have relapsed after or are ineligible for CAR-T cell therapy. These findings highlight MT-601’s potential to address unmet needs in heavily pre-treated lymphoma patients and could impact the company’s industry positioning by offering new hope to patients who have exhausted multiple treatment lines.
The most recent analyst rating on (MRKR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Marker Therapeutics stock, see the MRKR Stock Forecast page.
Spark’s Take on MRKR Stock
According to Spark, TipRanks’ AI Analyst, MRKR is a Neutral.
Marker Therapeutics is positioned in the biotechnology industry, characterized by high potential but also significant risks. The company exhibits strong revenue growth but faces challenges with profitability and cash flow. Technical indicators present a mixed outlook, with some potential for price reversals. The valuation reflects typical industry dynamics, favoring growth over profitability. Investors should be cautious, focusing on the company’s ability to manage cash flow and improve operational efficiencies to support future growth.
To see Spark’s full report on MRKR stock, click here.
More about Marker Therapeutics
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company that develops next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. Founded at Baylor College of Medicine, the company focuses on introducing novel T cell therapies to improve patient outcomes.
Average Trading Volume: 1,217,255
Technical Sentiment Signal: Sell
Current Market Cap: $16.3M
For an in-depth examination of MRKR stock, go to TipRanks’ Overview page.